You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKesson
Johnson and Johnson
Harvard Business School
Baxter

Last Updated: February 23, 2024

CLINICAL TRIALS PROFILE FOR ZANUBRUTINIB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Zanubrutinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02569476 ↗ BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies Completed BeiGene Phase 1 2016-01-13 This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
NCT02795182 ↗ Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies Completed BeiGene Phase 1 2016-06-29 This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in participants with B-cell lymphoid malignancies.
NCT02914938 ↗ A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting Clinipace LTD Phase 1 2016-10-01 A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
NCT02914938 ↗ A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting MEI Pharma, Inc. Phase 1 2016-10-01 A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
NCT03053440 ↗ A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) Active, not recruiting BeiGene Phase 3 2017-01-25 This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 (Zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
NCT03088878 ↗ A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Recruiting California Institute for Regenerative Medicine (CIRM) Phase 1/Phase 2 2018-01-03 This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zanubrutinib

Condition Name

Condition Name for Zanubrutinib
Intervention Trials
Diffuse Large B Cell Lymphoma 11
Mantle Cell Lymphoma 9
Small Lymphocytic Lymphoma 9
Chronic Lymphocytic Leukemia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zanubrutinib
Intervention Trials
Lymphoma 48
Lymphoma, Large B-Cell, Diffuse 26
Lymphoma, B-Cell 25
Leukemia, Lymphocytic, Chronic, B-Cell 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zanubrutinib

Trials by Country

Trials by Country for Zanubrutinib
Location Trials
United States 167
China 150
Australia 57
Japan 19
United Kingdom 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zanubrutinib
Location Trials
New York 12
Florida 12
Texas 12
New Jersey 10
California 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zanubrutinib

Clinical Trial Phase

Clinical Trial Phase for Zanubrutinib
Clinical Trial Phase Trials
Phase 3 12
Phase 2/Phase 3 1
Phase 2 53
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zanubrutinib
Clinical Trial Phase Trials
Recruiting 40
Not yet recruiting 28
Completed 13
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zanubrutinib

Sponsor Name

Sponsor Name for Zanubrutinib
Sponsor Trials
BeiGene 37
National Cancer Institute (NCI) 4
Ruijin Hospital 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zanubrutinib
Sponsor Trials
Other 71
Industry 48
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Express Scripts
Dow
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.